Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

New York University presents new PGRN variants for inflammation

Oct. 1, 2012

UCB's phase IIb study of olokizumab meets primary endpoint

Sep. 28, 2012

Antares Pharma reports data from actual human use study of Vibex methotrexate

Sep. 27, 2012

MorphoSys reports phase Ib/IIa MOR-103 study results

Sep. 25, 2012

Janssen files BLA for intravenous Simponi in rheumatoid arthritis

Sep. 19, 2012

America Stem Cell receives grant to study platform technology with amniotic fluid-derived stem cells

Sep. 19, 2012

Researchers design the first inhibitors of neurotrypsin, a molecular target for sarcopenia

Sep. 19, 2012

Novel antirheumatic drug iguratimod launched in Japan

Sep. 12, 2012

Zalicus reports topline phase IIb results for Synavive in rheumatoid arthritis

Sep. 12, 2012

Apremilast demonstrates significant clinical benefit in phase III studies

Sep. 7, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...